Author: russellrope

Study: Cannabis Consumption Associated With Opioid Cessation in Polydrug Users

Vancouver, British Columbia: Polydrug consumers are more likely to cease using non-prescription opioids if they consume cannabis, according to data published in the journal Drug and Alcohol Review.

Researchers affiliated with the University of British Columbia assessed the relationship between the use of cannabis and unregulated opioids among people who use drugs (PWUD) living with chronic pain.

They reported that the daily use of cannabis was positively associated with opioid cessation, particularly among males.

“Participants reporting daily cannabis use exhibited higher rates of cessation compared to less frequent users or non-users,” the study’s authors concluded. “Our findings add to the growing evidence supporting the potential benefits of cannabis use among PWUD, underlining the need for further research.”

The findings are consistent with prior data suggesting that cannabis use can mitigate opioid-related cravings and manage withdrawal symptoms.

Full text of the study, “Cannabis use and illicit opioid cessation among people who use drugs living with chronic pain,” appears in Drug and Alcohol Review.

Clinical Trial: Hemp-Derived Cannabinoids Improve Sleep Quality

Jacksonville, FL: The oral administration of a hemp-derived supplement containing precise percentages of THC, CBN, and CBD is associated with improved sleep quality, according to placebo-controlled trial data published in Health Science Reports.

Researchers affiliated with the University of North Florida and Jacksonville University assessed the impact of an orally administered cannabinoid supplement versus a placebo in 20 subjects with subthreshold insomnia symptoms.

Compared to the placebo, cannabinoid administration was associated with “significant improvements [from] baseline for sleep latency, sleep duration, and global sleep quality.” Participants also experienced “significant improvements in ‘mental health,’ [and] ‘feeling healthy and full of energy’” after using the cannabinoid supplement for ten days.

“The purpose [of this trial] was to examine the effectiveness of a hemp‐based supplement with CBD, CBN, THC, and a standardized terpene blend on sleep quality/quantity, anxiety, perceived stress, mood, pain, and HRQoL (health-related quality of life) in adults with subthreshold insomnia symptoms using a randomized double‐blind placebo‐controlled crossover pilot trial. We found the CS (cannabinoid supplement) was well‐tolerated and resulted in significant improvements in several sleep quality and health outcomes compared to both baseline and placebo,” the study’s authors concluded. “Improvements in daytime fatigue, pain affected sleep, mood, and anxiety were also associated with CS, though these were nonsignificant condition differences. In conclusion, [hemp-derived cannabinoid] supplementation may be a simple, effective, and well‐tolerated alternative to improve sleep quality and related health outcomes in adults with subthreshold insomnia symptoms.”

The trial’s results are consistent with those of several observational studies finding that patients with insomnia and other sleep disorders experience improvements following their use of cannabis. Studies have also identified a correlation between the adoption of statewide marijuana legalization laws and declining sales of over-the-counter (OTC) sleep aid medications.

Full text of the study, “Effectiveness of a cannabinoid supplement on sleep and mood in adults with subthreshold insomnia: A randomized double-blind placebo-controlled crossover pilot trial,” appears in Health Science Reports.

Texas: Judge Denies Effort To Enjoin Dallas’ Voter-Approved Marijuana Depenalization Ordinance

Dallas, TX: A Texas judge has denied a request from the state’s Republican Attorney General to enjoin Dallas’ voter-approved marijuana depenalization ordinance.

On Election Day, voters in Dallas (population 1.3 million) and two other cities (Bastrop and Lockhart) decided in favor of municipal ballot initiatives limiting the ability of local law enforcement to make misdemeanor marijuana possession arrests. Following the election, state Attorney General Ken Paxton filed litigation to prevent Dallas officials from implementing the law. (City officials in Bastrop and Lockhart declined to adopt their ordinances out of fear of litigation.)

In recent months, Paxton has filed lawsuits against multiple cities that have moved to end low-level marijuana arrests. To date, none of his lawsuits have been successful.

State law defines marijuana possession of 2 ounces or less as a criminal misdemeanor, punishable by up to 180 days in jail, a $2,000 fine, and a criminal record. According to data compiled by Texas NORML, police made an estimated 219,000 marijuana-related arrests between 2017 and 2021. Ninety-seven percent of those arrested were charged with possession only. Fifty-six percent of those arrested were under 25 years of age.

Additional information is available from Ground Game Texas.

Montana: Opponents of THC Limit Bill Outnumber Proponents by More Than 2 to 1 During Legislative Hearing

Helena, MT: Opponents of legislation imposing a 15 percent THC potency cap on adult-use marijuana products made their voices heard at a legislative hearing last week before members of the Senate Business, Labor and Economic Affairs committee.

Opponents of the bill, Senate Bill 443, outnumbered proponents by a margin of more than two to one. Many witnesses represented state-licensed cannabis businesses, who argued that passage of the measure would recriminalize most of their products. Others argued that the bill sought to unreasonably undermine the state’s marijuana legalization law, which was approved by 57 percent of voters.

NORML’s Deputy Director Paul Armentano provided testimony against the bill, stating: “Prohibiting adults from accessing products with more than 15 percent THC from state-licensed retailers will not eliminate consumers’ demand for them. Rather, it will encourage consumers to seek out these products in the unregulated market. It will also move the production of these products exclusively underground – thereby undermining the primary goal of legalization, which is to provide adults with safe, affordable, above-ground access to lab-tested products of known purity, potency, and quality.”

Some witnesses also pushed back against language in the bill equating the availability of higher-THC products with slavery.

In 2021, lawmakers approved legislation imposing a 35 percent THC potency limit on botanical products. They also capped the amount of THC permissible in edible products and concentrates. Montana is one of the only states in the nation to impose limits on the THC content of legally regulated cannabis products.

Following the hearing, committee members moved to table the bill – thereby suspending it from further consideration. A motion to reconsider the bill also failed.

Separate legislation, Senate Bill 255, establishing a mandatory registry for cannabis consumers and tracking their purchases was also scheduled to be debated last week, but it was never brought before the committee.